{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:10:44Z","timestamp":1783008644294,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["21K08469T"],"award-info":[{"award-number":["21K08469T"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s10067-024-06904-9","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T08:02:57Z","timestamp":1707465777000},"page":"1023-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of subcutaneous belimumab on disease activity, patient satisfaction, and metabolic profile in long-lasting systemic lupus erythematosus"],"prefix":"10.1007","volume":"43","author":[{"given":"Maya","family":"Yamato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-3494","authenticated-orcid":false,"given":"Tsuyoshi","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusho","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"3","key":"6904_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q (2023) Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 82(3):351\u2013356. https:\/\/doi.org\/10.1136\/ard-2022-223035","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6904_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/clpt.2011.290","volume":"91","author":"GJ Dennis","year":"2012","unstructured":"Dennis GJ (2012) Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther 91(1):143\u2013149. https:\/\/doi.org\/10.1038\/clpt.2011.290","journal-title":"Clin Pharmacol Ther"},{"issue":"5425","key":"6904_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1126\/science.285.5425.260","volume":"285","author":"PA Moore","year":"1999","unstructured":"Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285(5425):260\u2013263. https:\/\/doi.org\/10.1126\/science.285.5425.260","journal-title":"Science"},{"issue":"11","key":"6904_CR4","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189(11):1747\u20131756. https:\/\/doi.org\/10.1084\/jem.189.11.1747","journal-title":"J Exp Med"},{"issue":"9","key":"6904_CR5","first-page":"1955","volume":"30","author":"DD Gladman","year":"2003","unstructured":"Gladman DD, Urowitz MB, Rahman P, Iba\u00f1ez D, Tam LS (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30(9):1955\u20131959","journal-title":"J Rheumatol"},{"issue":"5","key":"6904_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2217\/ijr.15.33","volume":"10","author":"J Hong","year":"2015","unstructured":"Hong J, Maron DJ, Shirai T, Weyand CM (2015) Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. Int J Clin Rheumtol 10(5):365\u2013381. https:\/\/doi.org\/10.2217\/ijr.15.33","journal-title":"Int J Clin Rheumtol"},{"issue":"3","key":"6904_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/08916934.2015.1027815","volume":"48","author":"T Shirai","year":"2015","unstructured":"Shirai T, Hilhorst M, Harrison DG, Goronzy JJ, Weyand CM (2015) Macrophages in vascular inflammation\u2013from atherosclerosis to vasculitis. Autoimmunity 48(3):139\u2013151. https:\/\/doi.org\/10.3109\/08916934.2015.1027815","journal-title":"Autoimmunity"},{"issue":"3","key":"6904_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1084\/jem.20150900","volume":"213","author":"T Shirai","year":"2016","unstructured":"Shirai T, Nazarewicz RR, Wallis BB, Yanes RE, Watanabe R, Hilhorst M, Tian L, Harrison DG, Giacomini JC, Assimes TL, Goronzy JJ, Weyand CM (2016) The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med 213(3):337\u2013354. https:\/\/doi.org\/10.1084\/jem.20150900","journal-title":"J Exp Med"},{"issue":"12","key":"6904_CR9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","volume":"74","author":"M Zen","year":"2015","unstructured":"Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, Punzi L, Doria A (2015) Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 74(12):2117\u20132122. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207347","journal-title":"Ann Rheum Dis"},{"issue":"9767","key":"6904_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/s0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Le\u00f3n MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721\u2013731. https:\/\/doi.org\/10.1016\/s0140-6736(10)61354-2","journal-title":"Lancet"},{"issue":"8","key":"6904_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","volume":"71","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71(8):1343\u20131349. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200937","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"6904_CR12","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/cjn.02520322","volume":"17","author":"R Furie","year":"2022","unstructured":"Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, Green Y, Okily M, Madan A, Roth DA (2022) Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol 17(11):1620\u20131630. https:\/\/doi.org\/10.2215\/cjn.02520322","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"6904_CR13","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1007\/s10067-022-06287-9","volume":"41","author":"CR Escalera","year":"2022","unstructured":"Escalera CR, Guisado \u00c1MZ, Mateo FJ, Bahamontes-Rosa N, Villanueva MJG (2022) Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients. Clin Rheumatol 41(11):3373\u20133382. https:\/\/doi.org\/10.1007\/s10067-022-06287-9","journal-title":"Clin Rheumatol"},{"key":"6904_CR14","doi-asserted-by":"publisher","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstr\u00f8m K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirj\u00e1k L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kum\u00e1novics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, R\u00faa-Figueroa Fern\u00e1ndez \u00cd, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, D\u00f6rner T, Johnson SR (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71(9):1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","DOI":"10.1002\/art.40930"},{"issue":"Suppl 1","key":"6904_CR15","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","volume":"8","author":"MJ Atkinson","year":"2005","unstructured":"Atkinson MJ, Kumar R, Cappelleri JC, Hass SL (2005) Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 8(Suppl 1):S9-s24. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.00066.x","journal-title":"Value Health"},{"issue":"2","key":"6904_CR16","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288\u2013291","journal-title":"J Rheumatol"},{"key":"6904_CR17","doi-asserted-by":"publisher","unstructured":"Ugarte-Gil MF, Gamboa-Cardenas RV, Re\u00e1tegui-Sokolova C, Pimentel-Quiroz VR, Medina M, Elera-Fitzcarrald C, Zevallos F, Pastor-Asurza CA, Lofland J, Zazzetti F, Karyekar CS, Alarc\u00f3n GS, Perich-Campos RA (2022) LLDAS (lupus low disease activity state) and\/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort. Lupus Sci Med 9(1). https:\/\/doi.org\/10.1136\/lupus-2021-000616","DOI":"10.1136\/lupus-2021-000616"},{"issue":"12","key":"6904_CR18","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov\u00e1 D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918\u20133930. https:\/\/doi.org\/10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"6904_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road092","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, Matsumura R, Kawakami A, Hayashi N, Abreu G, Yavuz S, Lindholm C, Al-Mossawi H, Takeuchi T (2023) The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis. Mod Rheumatol. https:\/\/doi.org\/10.1093\/mr\/road092","journal-title":"Mod Rheumatol"},{"issue":"3","key":"6904_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/14397595.2018.1480915","volume":"29","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, Roth D (2019) Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a phase 3 randomized placebo-controlled trial. Mod Rheumatol 29(3):452\u2013460. https:\/\/doi.org\/10.1080\/14397595.2018.1480915","journal-title":"Mod Rheumatol"},{"key":"6904_CR21","doi-asserted-by":"publisher","unstructured":"Dima A, Jurcut C, Chasset F, Felten R, Arnaud L (2022) Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis 14:1759720x211073001. https:\/\/doi.org\/10.1177\/1759720x211073001","DOI":"10.1177\/1759720x211073001"},{"issue":"20","key":"6904_CR22","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.2169\/internalmedicine.5042-20","volume":"59","author":"Y Hosokawa","year":"2020","unstructured":"Hosokawa Y, Oiwa H (2020) Continuation rate, safety and efficacy of hydroxychloroquine treatment in a retrospective cohort of systemic lupus erythematosus in a Japanese municipal hospital. Intern Med 59(20):2485\u20132490. https:\/\/doi.org\/10.2169\/internalmedicine.5042-20","journal-title":"Intern Med"},{"issue":"11","key":"6904_CR23","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","volume":"71","author":"S Manzi","year":"2012","unstructured":"Manzi S, S\u00e1nchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D\u2019Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71(11):1833\u20131838. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200831","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6904_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"issue":"4","key":"6904_CR25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","volume":"7","author":"CE Collins","year":"2020","unstructured":"Collins CE, Cortes-Hern\u00e1ndez J, Garcia MA, von Kempis J, Schwarting A, Touma Z, Kurtinecz M, Gairy K (2020) Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the OBSErve studies. Rheumatol Ther 7(4):949\u2013965. https:\/\/doi.org\/10.1007\/s40744-020-00243-2","journal-title":"Rheumatol Ther"},{"issue":"4","key":"6904_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40744-022-00454-9","volume":"9","author":"SP Huang","year":"2022","unstructured":"Huang SP, Snedecor SJ, Nanji S, Lloyd E, Bell CF (2022) Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review. Rheumatol Ther 9(4):975\u2013991. https:\/\/doi.org\/10.1007\/s40744-022-00454-9","journal-title":"Rheumatol Ther"},{"issue":"3","key":"6904_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","volume":"81","author":"X Yu","year":"2023","unstructured":"Yu X, Chen N, Xue J, Mok CC, Bae SC, Peng X, Chen W, Ren H, Li X, Noppakun K, Gilbride JA, Green Y, Ji B, Liu C, Madan A, Okily M, Tang CH, Roth DA (2023) Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the east Asian population. Am J Kidney Dis 81(3):294-306.e291. https:\/\/doi.org\/10.1053\/j.ajkd.2022.06.013","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"6904_CR28","doi-asserted-by":"publisher","first-page":"e000118","DOI":"10.1136\/lupus-2015-000118","volume":"3","author":"CE Collins","year":"2016","unstructured":"Collins CE, Dall\u2019Era M, Kan H, Macahilig C, Molta C, Koscielny V, Chang DJ (2016) Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med 3(1):e000118. https:\/\/doi.org\/10.1136\/lupus-2015-000118","journal-title":"Lupus Sci Med"},{"key":"6904_CR29","doi-asserted-by":"publisher","unstructured":"Wu J, Mackie SL, Pujades-Rodriguez M (2020) Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis. BMJ Open Diabetes Res Care 8(1). https:\/\/doi.org\/10.1136\/bmjdrc-2020-001220","DOI":"10.1136\/bmjdrc-2020-001220"},{"key":"6904_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/oarrr.s245662","volume":"12","author":"N Atik","year":"2020","unstructured":"Atik N, Hayati RU, Hamijoyo L (2020) Correlation between steroid therapy and lipid profile in systemic lupus erythematosus patients. Open Access Rheumatol 12:41\u201346. https:\/\/doi.org\/10.2147\/oarrr.s245662","journal-title":"Open Access Rheumatol"},{"issue":"2","key":"6904_CR31","first-page":"230","volume":"18","author":"C Siegert","year":"1991","unstructured":"Siegert C, Daha M, Westedt ML, van der Voort E, Breedveld F (1991) IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 18(2):230\u2013234","journal-title":"J Rheumatol"},{"issue":"5","key":"6904_CR32","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/ki.1997.464","volume":"52","author":"LA Haseley","year":"1997","unstructured":"Haseley LA, Wisnieski JJ, Denburg MR, Michael-Grossman AR, Ginzler EM, Gourley MF, Hoffman JH, Kimberly RP, Salmon JE (1997) Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. Kidney Int 52(5):1375\u20131380. https:\/\/doi.org\/10.1038\/ki.1997.464","journal-title":"Kidney Int"},{"key":"6904_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1196\/annals.1313.020","volume":"1050","author":"RA Sinico","year":"2005","unstructured":"Sinico RA, Radice A, Ikehata M, Giammarresi G, Corace C, Arrigo G, Bollini B, Li Vecchi M (2005) Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci 1050:193\u2013200. https:\/\/doi.org\/10.1196\/annals.1313.020","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"6904_CR34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1053\/ajkd.2001.22071","volume":"37","author":"G Moroni","year":"2001","unstructured":"Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, Testoni C, Tincani A, Banfi G, Balestrieri G, Schifferli JA, Meroni PL, Ponticelli C (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37(3):490\u2013498. https:\/\/doi.org\/10.1053\/ajkd.2001.22071","journal-title":"Am J Kidney Dis"},{"key":"6904_CR35","doi-asserted-by":"publisher","first-page":"498703","DOI":"10.3389\/fimmu.2020.498703","volume":"11","author":"K Akita","year":"2020","unstructured":"Akita K, Yasaka K, Shirai T, Ishii T, Harigae H, Fujii H (2020) Interferon alpha enhances B cell activation associated with FOXM1 induction: potential novel therapeutic strategy for targeting the plasmablasts of systemic lupus erythematosus. Front Immunol 11:498703. https:\/\/doi.org\/10.3389\/fimmu.2020.498703","journal-title":"Front Immunol"},{"issue":"4","key":"6904_CR36","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1186\/ar3897","volume":"14","author":"T Shirai","year":"2012","unstructured":"Shirai T, Fujii H, Ono M, Nakamura K, Watanabe R, Tajima Y, Takasawa N, Ishii T, Harigae H (2012) A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus. Arthritis Res Ther 14(4):R157. https:\/\/doi.org\/10.1186\/ar3897","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"6904_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-023-03186-5","volume":"25","author":"K Yasaka","year":"2023","unstructured":"Yasaka K, Yamazaki T, Sato H, Shirai T, Cho M, Ishida K, Ito K, Tanaka T, Ogasawara K, Harigae H, Ishii T, Fujii H (2023) Phospholipase D4 as a signature of toll-like receptor 7 or 9 signaling is expressed on blastic T-bet + B cells in systemic lupus erythematosus. Arthritis Res Ther 25(1):200. https:\/\/doi.org\/10.1186\/s13075-023-03186-5","journal-title":"Arthritis Res Ther"},{"key":"6904_CR38","doi-asserted-by":"publisher","unstructured":"Beaupere C, Liboz A, F\u00e8ve B, Blondeau B, Guillemain G (2021) Molecular mechanisms of glucocorticoid-induced insulin resistance. Int J Mol Sci 22(2). https:\/\/doi.org\/10.3390\/ijms22020623","DOI":"10.3390\/ijms22020623"},{"issue":"9","key":"6904_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"JX Li","year":"2022","unstructured":"Li JX, Cummins CL (2022) Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 18(9):540\u2013557. https:\/\/doi.org\/10.1038\/s41574-022-00683-6","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"6904_CR40","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","volume":"60","author":"AJ Peckett","year":"2011","unstructured":"Peckett AJ, Wright DC, Riddell MC (2011) The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism 60(11):1500\u20131510. https:\/\/doi.org\/10.1016\/j.metabol.2011.06.012","journal-title":"Metabolism"},{"key":"6904_CR41","doi-asserted-by":"publisher","unstructured":"Floris A, Chessa E, Sebastiani GD, Prevete I, Iannone F, Coladonato L, Govoni M, Bortoluzzi A, Mosca M, Tani C, Doria A, Iaccarino L, Franceschini F, Fredi M, Conti F, Spinelli FR, Bellisai F, D'Alessandro R, Zanetti A, Carrara G, Scir\u00e8 CA, Cauli A, Piga M (2022) Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study. RMD Open 8(2). https:\/\/doi.org\/10.1136\/rmdopen-2022-002701","DOI":"10.1136\/rmdopen-2022-002701"},{"key":"6904_CR42","doi-asserted-by":"publisher","unstructured":"Kopin L, Lowenstein C (2017) Dyslipidemia. Ann Intern Med 167(11):Itc81-itc96. https:\/\/doi.org\/10.7326\/aitc201712050","DOI":"10.7326\/aitc201712050"},{"issue":"5","key":"6904_CR43","doi-asserted-by":"publisher","first-page":"e229953","DOI":"10.1001\/jamanetworkopen.2022.9953","volume":"5","author":"Y Lu","year":"2022","unstructured":"Lu Y, Li SX, Liu Y, Rodriguez F, Watson KE, Dreyer RP, Khera R, Murugiah K, D\u2019Onofrio G, Spatz ES, Nasir K, Masoudi FA, Krumholz HM (2022) Sex-specific risk factors associated with first acute myocardial infarction in young adults. JAMA Netw Open 5(5):e229953. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.9953","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6904_CR44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12967-023-04047-0","volume":"21","author":"S Lu","year":"2023","unstructured":"Lu S, Xie Q, Kuang M, Hu C, Li X, Yang H, Sheng G, Xie G, Zou Y (2023) Lipid metabolism, BMI and the risk of nonalcoholic fatty liver disease in the general population: evidence from a mediation analysis. J Transl Med 21(1):192. https:\/\/doi.org\/10.1186\/s12967-023-04047-0","journal-title":"J Transl Med"},{"issue":"1","key":"6904_CR45","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12882-022-02932-2","volume":"23","author":"M Weldegiorgis","year":"2022","unstructured":"Weldegiorgis M, Woodward M (2022) Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the United Kingdom. BMC Nephrol 23(1):312. https:\/\/doi.org\/10.1186\/s12882-022-02932-2","journal-title":"BMC Nephrol"},{"issue":"3","key":"6904_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11883-012-0307-3","volume":"15","author":"C Reitz","year":"2013","unstructured":"Reitz C (2013) Dyslipidemia and the risk of Alzheimer\u2019s disease. Curr Atheroscler Rep 15(3):307. https:\/\/doi.org\/10.1007\/s11883-012-0307-3","journal-title":"Curr Atheroscler Rep"},{"issue":"9493","key":"6904_CR47","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/s0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267\u20131278. https:\/\/doi.org\/10.1016\/s0140-6736(05)67394-1","journal-title":"Lancet"},{"key":"6904_CR48","doi-asserted-by":"publisher","unstructured":"(2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama 285(19):2486\u20132497. https:\/\/doi.org\/10.1001\/jama.285.19.2486","DOI":"10.1001\/jama.285.19.2486"},{"key":"6904_CR49","doi-asserted-by":"publisher","first-page":"108637","DOI":"10.1016\/j.clim.2020.108637","volume":"222","author":"B Campos-L\u00f3pez","year":"2021","unstructured":"Campos-L\u00f3pez B, Meza-Meza MR, Parra-Rojas I, Ruiz-Ballesteros AI, Vizmanos-Lamotte B, Mu\u00f1oz-Valle JF, Montoya-Buelna M, Cerpa-Cruz S, Bernal-Hern\u00e1ndez LE, De la Cruz-Mosso U (2021) Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients: a cross-sectional study. Clin Immunol 222:108637. https:\/\/doi.org\/10.1016\/j.clim.2020.108637","journal-title":"Clin Immunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06904-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T11:14:46Z","timestamp":1708600486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06904-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6904"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06904-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol complied with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Tohoku University Graduate School of Medicine (reference number: 2022\u20131-775). Written informed consent was not required because of the retrospective observational nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}